研究者情報 | |
ミヤベ チエ
MIYABE CHIE 宮部千恵 所属 大学院附属研究所 難病治療研究センター 職種 講師 |
|
論文種別 | 総説・解説 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Chemokines and chemokine receptors as promising targets in rheumatoid arthritis |
掲載誌名 | 正式名:Front Immunol ISSNコード:16643224 |
掲載区分 | 国外 |
巻・号・頁 | 14,1100869頁 |
著者・共著者 | Murayama M.A, Shimizu J, Miyabe C, Yudo K, Miyabe Y. |
発行年月 | 2023/02 |
概要 | Rheumatoid arthritis (RA) is an autoimmune disease that commonly causes inflammation and bone destruction in multiple joints. Inflammatory cytokines, such as IL-6 and TNF-α, play important roles in RA development and pathogenesis. Biological therapies targeting these cytokines have revolutionized RA therapy. However, approximately 50% of the patients are non-responders to these therapies. Therefore, there is an ongoing need to identify new therapeutic targets and therapies for patients with RA. In this review, we focus on the pathogenic roles of chemokines and their G-protein-coupled receptors (GPCRs) in RA. Inflamed tissues in RA, such as the synovium, highly express various chemokines to promote leukocyte migration, tightly controlled by chemokine ligand-receptor interactions. Because the inhibition of these signaling pathways results in inflammatory response regulation, chemokines and their receptors could be promising targets for RA therapy. The blockade of various chemokines and/or their receptors has yielded prospective results in preclinical trials using animal models of inflammatory arthritis. However, some of these strategies have failed in clinical trials. Nonetheless, some blockades showed promising results in early-phase clinical trials, suggesting that chemokine ligand-receptor interactions remain a promising therapeutic target for RA and other autoimmune diseases. |
DOI | 10.3389/fimmu.2023.1100869 |
文献番号 | 36860872 |